David McConkey
Overview
Explore the profile of David McConkey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
1351
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Razavi S, Khan A, Fu D, Mayer D, McConkey D, Putluri N, et al.
Curr Opin Oncol
. 2025 Mar;
PMID: 40071441
Purpose Of Review: This review examines the existing literature on metabolic pathways associated with bladder cancer (BC) and investigates four domains: (1) diagnoses, (2) cancer classification (staging & grading), (3)...
2.
Apolo A, Baumann B, Al-Ahmadie H, Ballas L, Bangs R, Brothers K, et al.
Bladder Cancer
. 2025 Mar;
11(1):23523735251319185.
PMID: 40034245
The National Cancer Institute organized a virtual Clinical Trials Planning Meeting (CTPM) on 'Defining the next generation of clinical trials with combination therapies in non-muscle invasive bladder cancer (NMIBC)' led...
3.
Steinmetz A, Jazayeri B, Pierce M, Mokkapati S, McConkey D, Li R, et al.
Expert Opin Biol Ther
. 2025 Jan;
25(2):149-159.
PMID: 39779686
Introduction: Approximately 75% of bladder cancer cases are non-muscle invasive at diagnosis. Drug development for non-muscle invasive bladder cancer (NMIBC) has historically lagged behind that of other malignancies. No treatment...
4.
Sadhukhan P, Feng M, Illingworth E, Illingworth E, Sloma I, Ooki A, et al.
J Clin Invest
. 2024 Dec;
135(2.
PMID: 39630608
The Hippo signaling pathway plays a key role in tumorigenesis in different cancer types. We investigated the role of the Hippo effector YAP1 in the tumor immune microenvironment (TIME) of...
5.
Li R, Hensley P, Gupta S, Al-Ahmadie H, Babjuk M, Black P, et al.
Eur Urol
. 2024 Aug;
86(6):516-527.
PMID: 39183090
Background And Objective: There has been a recent surge in the development of agents for bacillus Calmette-Guérin-unresponsive (BCG-U) non-muscle-invasive bladder cancer (NMIBC). Critical assessment of these agents and practical recommendations...
6.
Steinmetz A, Mokkapati S, McConkey D, Dinney C
Bladder Cancer
. 2024 Aug;
10(2):105-112.
PMID: 39131870
Background: The intravesical gene therapy nadofaragene firadenovec (rAd-IFNα/Syn3) was FDA approved in 2022 for non-muscle invasive bladder cancer (NMIBC) unresponsive to frontline treatment with BCG, and the first gene therapy...
7.
Radvanyi F, Real F, McConkey D
Bladder Cancer
. 2024 Jul;
9(4):299-304.
PMID: 38994248
In an accompanying paper, Mattias Höglund discusses on what is a bladder cancer molecular subtype. He emphasizes the need to consider the aim of tumor classification, which is obviously critical...
8.
Vlachou E, Johnson B, McConkey D, Jing Y, Matoso A, Hahn N, et al.
Front Oncol
. 2024 Jun;
14:1377842.
PMID: 38933451
Introduction: Enfortumab vedotin (EV) is an antibody drug conjugate approved for advanced urothelial cancer, consisting of a monomethyl auristatin E payload linked to a human monoclonal antibody targeting nectin-4. No...
9.
Lee S, Bondaruk J, Wang Y, Chen H, Lee J, Majewski T, et al.
Cell Rep
. 2024 Apr;
43(5):114146.
PMID: 38676926
We describe a strategy that combines histologic and molecular mapping that permits interrogation of the chronology of changes associated with cancer development on a whole-organ scale. Using this approach, we...
10.
Czerniak B, Lee S, Jung S, Kus P, Bondaruk J, Lee J, et al.
Res Sq
. 2024 Apr;
PMID: 38659962
Multi-platform mutational, proteomic, and metabolomic spatial mapping was used on the whole-organ scale to identify the molecular evolution of bladder cancer from mucosal field effects. We identified complex proteomic and...